IP Library Granted Patent US 11,596,798
Granted Patent B2
US 11,596,798 · App. 17/030,349 · Granted Mar 7, 2023

Treatment of congestive heart failure with electrical stimulation, and associated systems and methods

Inventors: James R. Thacker (Homer, AK); Kerry Bradley (Glendale, CA)
Assignee: Nevro Corp
A61N1/3627A61N1/36114A61N1/36139A61N1/36171A61N1/056
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,596,798
App. No.
17/030,349
Granted
Mar 7, 2023
Kind
B2
Abstract

Systems and methods for treating congestive heart failure with high frequency stimulation are disclosed. A representative method for treating a patient includes applying an electrical signal having a frequency of from about 1 kHz to about 100 kHz to the patient via a treatment system that includes a signal delivery element in electrical communication with the patient's vagus nerve at a portion of the vagus nerve located at or proximate to the anterior interventricular junction of the patient's heart. The method can further include automatically detecting at least one physiological parameter of the patient, automatically determining at least one of an ejection fraction of the patient's heart and a correlate of the ejection fraction based on the detected parameter, and automatically adjusting the applied signal based on the determined ejection fraction.

Claims (34)

1. A method for treating congestive heart failure in a patient, comprising:

applying an electrical signal to the patient via a treatment system to excite neural tissue proximate and/or within an epicardial fat pad of the patient's heart wherein the treatment system includes a signal delivery element positioned at the epicardial fat pad of the patient's heart, the electrical signal having a frequency in a range of from about 1 kHz to about 100 kHz;

automatically detecting at least one physiological parameter of the patient via one or more sensing elements;

based on the detected parameter, automatically determining an ejection fraction indicator that is at least one of an ejection fraction of the patient's heart and a correlate of the ejection fraction; and

automatically adjusting the applied signal based on the determined ejection fraction indicator.

2. The method of claim 1 wherein automatically adjusting the applied signal includes stopping the application of the applied signal in response to detecting an ejection fraction indicator greater than or equal to a target ejection fraction threshold.

3. The method of claim 1 wherein applying the electrical signal occurs at a first time, and wherein automatically adjusting the applied signal includes applying the electrical signal at a second time in response to detecting an ejection fraction indicator less than the target ejection fraction threshold.

4. The method of claim 1 wherein automatically adjusting the applied signal includes increasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to detecting an ejection fraction indicator less than a target ejection fraction threshold.

5. The method of claim 1 wherein automatically adjusting the applied signal includes decreasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to detecting an ejection fraction indicator greater than or equal to a target ejection fraction threshold.

6. The method of claim 1 wherein:

automatically detecting a physiological parameter includes automatically detecting the patient's heart rate; and

automatically adjusting the applied signal includes increasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to the increase in the patient's heart rate.

7. The method of claim 1 wherein applying the electrical signal includes applying the signal to the patient via a lead positioned at or proximate to the atrial-ventricular fat pads of the patient's heart.

8. The method of claim 1 wherein applying the electrical signal includes applying the signal with a pulse width less than or equal to 1/(2×the frequency of the signal).

9. The method of claim 1 wherein the treatment system includes an implantable treatment system.

10. The method of claim 1 wherein the at least one detected physiological parameter includes at least one of the patient's heart rate, the patient's blood pressure, and the patient's blood flow rate.

11. A method for treating congestive heart failure in a patient, comprising:

applying an electrical signal to the patient via a treatment system to increase a contraction strength of a left ventricle and/or a right ventricle of the patient's heart, wherein the treatment system includes a signal delivery element positioned at an epicardial fat pad of the patient's heart, and wherein the electrical signal has a frequency in a range of from about 1 kHz to about 100 kHz;

automatically detecting at least one physiological parameter of the patient via one or more sensing elements;

based on the detected parameter, automatically determining an ejection fraction indicator that is at least one of an ejection fraction of the patient's heart and a correlate of the ejection fraction; and

automatically adjusting the applied signal based on the determined ejection fraction indicator.

12. The method of claim 11 wherein applying the electric signal increases the contraction strength of the left ventricle.

13. The method of claim 11 wherein applying the electric signal increases the contraction strength of the right ventricle.

14. The method of claim 11 wherein automatically adjusting the applied signal includes stopping the application of the applied signal in response to detecting an ejection fraction indicator greater than or equal to a target ejection fraction threshold.

15. The method of claim 11 wherein applying the electrical signal occurs at a first time, and wherein automatically adjusting the applied signal includes applying the electrical signal at a second time in response to detecting an ejection fraction indicator less than the target ejection fraction threshold.

16. The method of claim 11 wherein automatically adjusting the applied signal includes increasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to detecting an ejection fraction indicator less than a target ejection fraction threshold.

17. The method of claim 11 wherein automatically adjusting the applied signal includes decreasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to detecting an ejection fraction indicator greater than or equal to a target ejection fraction threshold.

18. The method of claim 11 wherein:

automatically detecting a physiological parameter includes automatically detecting the patient's heart rate; and

automatically adjusting the applied signal includes increasing at least one of an amplitude of the applied signal and a pulse width of the applied signal in response to the increase in the patient's heart rate.

19. The method of claim 11 wherein applying the electrical signal includes applying the signal to the patient via a lead positioned at or proximate to the atrial-ventricular fat pads of the patient's heart.

20. The method of claim 11 wherein applying the electrical signal includes applying the signal with a pulse width less than or equal to 1/(2×the frequency of the signal).

21. The method of claim 11 wherein the treatment system includes an implantable treatment system.

22. The method of claim 11 wherein the at least one detected physiological parameter includes at least one of the patient's heart rate, the patient's blood pressure, and the patient's blood flow rate.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 4, 2025
From: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
To: NEVRO CORP.
Reel/Frame 070743/0001 →
PATENT SECURITY AGREEMENT Recorded Dec 1, 2023
From: NEVRO CORP.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 065744/0302 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 13, 2021
From: THACKER, JAMES R.; BRADLEY, KERRY
To: NEVRO CORP.
Reel/Frame 057786/0001 →
Continuity (3)
Division 15414561 · Jan 24, 2017
Provisional Application 62286892 · Jan 25, 2016
Related Publication 20210060338A1 · Mar 4, 2021
Cited By (1)
US 12,654,018